Derrick Thibodeaux
Family · Vinton, LANPI 1659762839
Payments from drug & device makers
Across 292 payments — averaging $14.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$310
- Takeda Pharmaceuticals U.S.A., Inc.$296
- Lilly USA, LLC$273
- Boehringer Ingelheim$250
- Vanda Pharmaceuticals Inc.$222
- plus $1K from 17 others
What the payments were for
- Food & beverage$4,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,588 |
| Novo Nordisk | 19 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $296 |
| Lilly USA, LLC | 16 | $273 |
| Boehringer Ingelheim | 15 | $250 |
| Vanda Pharmaceuticals Inc. | 11 | $222 |
| Amgen | 18 | $206 |
| Esperion Therapeutics, Inc. | 13 | $205 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $192 |
| Abbott | 9 | $178 |
| AstraZeneca | 7 | $110 |
| Pfizer | 5 | $94 |
| Corium, LLC | 6 | $86 |
| Bayer | 4 | $78 |
| Eisai Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Insulet Corporation | 1 | $15 |
| GSK | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,255 in reported general payments places this provider in the 85th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 99 | $118,459 |
| TrulicityDulaglutide | 91 | $114,152 |
| JardianceEmpagliflozin | 124 | $96,522 |
| OzempicSemaglutide | 78 | $76,396 |
| EliquisApixaban | 82 | $75,139 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 80 | $55,619 |
| FarxigaDapagliflozin Propanediol | 46 | $52,503 |
| XareltoRivaroxaban | 32 | $24,293 |
| Repatha SureclickEvolocumab | 35 | $22,110 |
| RybelsusSemaglutide | 13 | $20,075 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $16,290 |
| KerendiaFinerenone | 20 | $15,149 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $14,580 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $13,116 |
| LinzessLinaclotide | 16 | $10,867 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $273 | $232,611190 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $110 | $108,121126 claims |
| Boehringer IngelheimJardiance | $250 | $96,522124 claims |
| Novo NordiskOzempic, Rybelsus | $310 | $96,47291 claims |
| PfizerEliquis | $94 | $75,13982 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $15 | $29,40631 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $205 | $24,56238 claims |
| BayerKerendia | $78 | $15,14920 claims |
| AbbVieLinzess | $1,588 | $10,86716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,610 family providers in Louisiana.
Other family in Vinton
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.